Firms

Primer Capital

Primer Capital

Historical office:10 Ostozhenka,119034 Moscow,Russia

web.archive.orglinkedin.com

Primer Capital is the historically documented Moscow-based biotechnology and medical-technology venture investor whose institutional portfolio includes Acticor Biotech. Its archived primary site provides a substantive manager profile, team and scientific expert council, investing in drug development, medical devices and clinical software. The site was operating by2015, while its LinkedIn profile gives2017 as founding year; an exact legal incorporation/founding year is not independently verified and remains unknown. This profile is distinct from AlexisJi’s2023 Primer Ventures, Primera Capital, Seattle’s PE FundI series of Primer Capital LP, Irish Primer Capital DAC, Primer AI software and the payments company Primer. Acticor’s approved2021 statutory registration identifies the exact holder PRIMER CAPITAL I LP with73,160shares. Athira’s original May29,2020 SEC investors-rights agreement independently names Primer-Capital I LP and its general partner Primer Capital Partners, signed by GP director Sean Inggs. The manager brand, exact fund and GP are differentiated; no unsupported Russian company registration or sole individual owner is invented. Share counts or percent ownership are not acquisition cost or a fund cash close. The exact legal fund vehicle is recorded with undisclosed size and closing day. Media figures such as100MRUB,5MUSD or larger targets are not promoted to primary-verified LP closes. The full published archival roster contains seven operating/advisory people and three external scientific/investment expert-council members, plus the separately dated2019 executive director Maria Belousova. All roles are expressly historical. Managing partners Timur Avdeenko and Dmitry Sharov, CEO Anton Lavrentev, executive director/COO Elizaveta Rozhdestvenskaya, research manager Evgeny Shevchenko, adviser Nadezhda Kartashova and analyst/consultant Sofya Yartseva are distinguished from external advisers Catherine Boule, John Edward Butler-Ransohoff and Vadim Tarasov. Current Unicorn Capital Partners independently confirms Elizaveta’s Primer tenure ended in2022; its team is not transferred to Primer. The archive directly establishes AI/deeptech and neuroscience relevance: Botkin.AI medical imaging/clinical decision-support investment with reported11MRUB contribution, Data MATRIX clinical-data software, Acticor’s ischemic-stroke programme, vascular microcatheters at Bendit, molecular bacteriotherapy at MatriSys and oncology diagnostics. Regulatory approvals, treatment efficacy and current operating status of portfolio technologies require issuer/authority evidence; the portfolio descriptions establish investment/research relevance rather than clinical validation. Own archived portfolio and SEC-supported Athira relationships are queued for full issuer identity/financing audits. As ofOctober2026, the former primer-capital.com domain displays unrelated Indonesian education content. It is recorded solely as historical provenance through timestamped archives, not as a verified current manager website. Current manager operating status, updated public roster, exact registrations and fund legal status are unresolved. Historical genuine logo and available portraits are preserved; missing archived image files are documented rather than replaced with invented pictures. The Acticor callback is owned solely by issuer researcher625 and uses its matching source-qualified historical institutional-equity event, with ticket/date/stage unknown unless a stronger primary cash audit proves otherwise.

Founded
—
Type
Venture capital

Funds1

  • Primer Capital I LP—

    Exacthistoriclegalinvestmentvehicle inActicor2021approvedregistration andAthiraMay29,2020SECinvestors-rightscontract (hyphenatedPrimer-CapitalILP). GPPrimerCapitalPartners, signerGPdirectorSeanInggs. Exactregistrationjurisdiction/currentstatus/fundcashsize/closingdaynotindependentlyverified; sharesheld andportfoliocashnotLPfundraise. SeparatefromSeattlePEFundIseriesPrimerCapitalLP andothernamesakes.

Team

Operations and support

Anton LavrentevHistorical CEO — archived2021/2022; current tenure unverified
Catherine BouleCatherine BouleHistorical Advisory Board Member — archived2021/2022; current tenure unverified
Dmitry SharovHistorical Managing partner, Investment committee member — archived2021/2022; current tenure unverified
Elizaveta RozhdestvenskayaElizaveta RozhdestvenskayaFormer Executive Director / COO — primary-confirmed2016–2022, exact days unknown
Evgeny ShevchenkoEvgeny ShevchenkoHistorical Project Manager — archived2021/2022; current tenure unverified
John Edward Butler-RansohoffHistorical Advisory Board Member — archived2021/2022; current tenure unverified
Maria Belousova — Primer CapitalMaria Belousova — Primer CapitalHistorical executive director — published2019; subsequent tenure unknown
Nadezhda KartashovaNadezhda KartashovaHistorical Adviser — archived2021/2022; current tenure unverified
Sofya YartsevaSofya YartsevaHistorical Consultant — archived2021/2022; current tenure unverified
Timur AvdeenkoHistorical Managing partner, Investment committee member — archived2021/2022; current tenure unverified
Vadim TarasovVadim TarasovHistorical Advisory Board Member — archived2021/2022; current tenure unverified

Co-investing

Angels Santé

Investments